Elamipretide vs BI 456906
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | BI 456906 |
|---|---|---|
| Category | Muscle & Performance | Weight Management |
| Full Name | Elamipretide (MTP-131, SS-31) | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 639.8 Da | N/A |
| Half-Life | 1-4 hours | Approximately 1 week |
| Amino Acids | 4 | N/A |
| Typical Dose | 0.01-0.25 mg/kg/day | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous/Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 10 |
| Research Status | Clinical | Clinical |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.